Menstrual Blood Stem Cells in Poor Ovarian Responders

Phase 3 Completed 180 enrolled Avicenna Research Institute

Non-randomizedParallel-groupSingle-blindTreatment

Summary

In this controlled trial, poor ovarian responder women will be treated with transplantation of autologous menstrual blood stem cells. The investigators will attempt to assess the safety and efficacy of this procedure for the treatment of infertility in POR patients compared to control group.

Timeline

Start: 2020-06-21
Primary completion: 2021-09-22
Completion: 2022-10-22

Outcome

Met primary endpoint

paper Following the 2-month follow-up period, women who received MenSC treatment demonstrated a significantly higher rate of spontaneous pregnancy (P < 0.005) PMID 37968668 ↗

Publications

Zafardoust S, Kazemnejad S, Fathi-Kazerooni M, Darzi M, Sadeghi MR, Sadeghi Tabar A, Sehat Z. The effects of intraovarian injection of autologous menstrual blood-derived mesenchymal stromal cells on pregnancy outcomes in women with poor ovarian response. Stem Cell Res Ther. 2023 Nov 15;14(1):332. doi: 10.1186/s13287-023-03568-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Autologous Menstrual Blood Stem Cells	Unknown	0.15 ml	Other